The SEC moved today to suspend trading in Corix Bioscience (OTC: CXBS), questioning the accuracy of information it has provided:

The Commission temporarily suspended trading in the securities of Corix Bioscience, Inc. because of questions that have been raised about the accuracy and adequacy of publicly disseminated information concerning, among other things, the company’s assets and operations in Nevada. This information includes claims that CXBS holds a valid, state-issued export license in Nevada for growing, processing, and distributing industrial hemp.

The company’s website includes a copy of the license in question:

The company, which was previously known as IX Biotechnology, merged into American Housing Income Trust in March, 2017, subsequently changing its name. Corix stated that it intended to be the largest producer of CBD in the United States. The company, which is focused on California, Oregon and Nevada, claims to have operations in Africa and the UK as well as a license to import into Switzerland.

Corix hasn’t yet filed its 10-K for the year ending in December 2017, with its most recent 10-Q filed in November. Subsequent to that filing, it issued an 8-K that detailed claims that shareholder signatures had been forged:

Corix Bioscience, Inc., a Wyoming corporation (the “Company”) files this Current Report on Form 8-K to disclose information revealed to the Company through the sworn testimony of three shareholders: George Elam, William Bills, and Joaquin Flores (the “Shareholders”). The Shareholders claim that certain documents bearing their signatures are not authentic, were not signed by them, and were not signed with their permission.

Trading in the stock is suspended until April 27th.

Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.

Exclusive article by Alan Brochstein, CFA Facebook | LinkedIn | Email Based in Houston, Alan leverages his experience as founder of online communities 420 Investor , the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures , he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha , where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter